Edwin Moses, the former chief executive of Ablynx, has been appointed chair of the board of directors of Sensorion SA, a developer of treatments for hearing loss disorders. Dr Moses led Ablynx for more than 14 years until its acquisition by Sanofi SA in 2018. He was also CEO of the pharmaceutical services company Oxford Asymmetry International until its sale to Evotec SE in 2000. Dr Moses is currently chair of Achilles Therapeutics Ltd, Avantium NV and LabGenius Ltd, and is an operating partner of Keensight Capital.
He received a PhD in chemistry from Sheffield University in the UK.
Sensorion announced the appointment on 6 July 2020.
Copyright 2020 Evernow Publishing Ltd